Free tool
FAERS Monitor: Vijoice
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215039 or its brand name (Vijoice, Alpelisib). Reports on generic versions are filed under their own applications.
Reports
1,873
Serious
1,427
76% of reports
Hospitalization
498
Death reported
236
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hyperglycaemia351
- malignant neoplasm progression249
- rash210
- diarrhoea205
- fatigue127
- drug ineffective124
- nausea123
- breast cancer metastatic117
- death117
- metastases to bone94
- blood glucose increased92
- weight decreased91
- metastases to liver88
- decreased appetite85
- diabetes mellitus85
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 90 |
| 2020 | 172 |
| 2021 | 269 |
| 2022 | 402 |
| 2023 | 334 |
| 2024 | 228 |
| 2025 | 192 |
| 2026 | 177 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,286 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer metastaticSignal | 117 | 123.7 | 103.7 | 13,976 |
| hyperglycaemiaSignal | 351 | 109.2 | 99.3 | 37,231 |
| metastases to boneSignal | 94 | 64.7 | 53.1 | 5,801 |
| metastases to liverSignal | 88 | 56.5 | 46.1 | 4,725 |
| malignant neoplasm progressionSignal | 249 | 27.4 | 24.4 | 6,315 |
| diabetes mellitusSignal | 85 | 12.5 | 10.2 | 893 |
| blood glucose increasedSignal | 92 | 5.5 | 4.5 | 336 |
| rashSignal | 210 | 5.4 | 4.8 | 766 |
| decreased appetiteSignal | 85 | 4.1 | 3.3 | 199 |
| weight decreasedSignal | 91 | 3.7 | 3.0 | 176 |
| diarrhoeaSignal | 205 | 3.6 | 3.1 | 388 |
| fatigue | 127 | 1.8 | 1.5 | 49 |
| nausea | 123 | 1.7 | 1.5 | 40 |
| death | 117 | 1.5 | 1.3 | 22 |
| drug ineffective | 124 | 1.1 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.